Wei, X.; Kane, W.J.; Adair, S.J.; Nagdas, S.; Liu, D.; Bauer, T.W.
PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. Biomolecules 2025, 15, 948.
https://doi.org/10.3390/biom15070948
AMA Style
Wei X, Kane WJ, Adair SJ, Nagdas S, Liu D, Bauer TW.
PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. Biomolecules. 2025; 15(7):948.
https://doi.org/10.3390/biom15070948
Chicago/Turabian Style
Wei, Xiaolong, William J. Kane, Sara J. Adair, Sarbajeet Nagdas, Denis Liu, and Todd W. Bauer.
2025. "PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer" Biomolecules 15, no. 7: 948.
https://doi.org/10.3390/biom15070948
APA Style
Wei, X., Kane, W. J., Adair, S. J., Nagdas, S., Liu, D., & Bauer, T. W.
(2025). PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. Biomolecules, 15(7), 948.
https://doi.org/10.3390/biom15070948